Financials data is unavailable for this security.
View more
Year on year Gilead Sciences Inc had relatively flat revenues (27.28bn to 27.12bn), though the company grew net income 23.34% from 4.59bn to 5.66bn.
Gross margin | 77.80% |
---|---|
Net profit margin | 0.40% |
Operating margin | 2.90% |
Return on assets | 0.19% |
---|---|
Return on equity | 0.62% |
Return on investment | 0.24% |
More ▼
Cash flow in USDView more
In 2023, Gilead Sciences Inc increased its cash reserves by 12.44%, or 673.00m. The company earned 8.01bn from its operations for a Cash Flow Margin of 29.53%. In addition the company used 2.27bn on investing activities and also paid 5.13bn in financing cash flows.
Cash flow per share | 0.747 |
---|---|
Price/Cash flow per share | 128.68 |
Book value per share | 14.76 |
---|---|
Tangible book value per share | -8.40 |
More ▼
Balance sheet in USDView more
Current ratio | 1.11 |
---|---|
Quick ratio | 0.8208 |
Total debt/total equity | -- |
---|---|
Total debt/total capital | -- |
More ▼
Growth rates in USD
SmartText is unavailable
Div yield(5 year avg) | 3.86% |
---|---|
Div growth rate (5 year) | 5.64% |
Payout ratio (TTM) | 2,307.94% |
EPS growth(5 years) | 1.53 |
---|---|
EPS (TTM) vs TTM 1 year ago | -98.20 |
More ▼